November 7th Options Now Available For Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals (RXRX), trading at $4.79, offers distinct options strategies for investors: selling a $4.50 cash-secured put for 5 cents enables potential acquisition at a $4.45 effective cost basis (a 6% discount) with a 9.42% annualized premium return if it expires worthless. Concurrently, a covered call strategy, selling a $5.00 call for 15 cents, yields a 7.52% return if shares are called away by November 7th, or a 26.56% annualized premium return if the option expires worthless. These strategies are notable given the implied volatility for these options ranges from 231-237%, significantly exceeding RXRX's 91% trailing 12-month actual volatility, indicating high market expectations for future price fluctuations.

Analysis

The options market for Recursion Pharmaceuticals (RXRX) is signaling expectations of significant price movement, with implied volatility for near-term contracts at 231-237%, a stark contrast to the stock's 91% actual trailing twelve-month volatility. This elevated premium presents distinct opportunities for investors. For those bullish on the stock, selling the $4.50 strike put contract for a 5-cent premium could establish an effective cost basis of $4.45 per share—a 6% discount from the current $4.79 price—or generate a 9.42% annualized yield on cash if the option expires worthless, an event with a 67% statistical probability. Conversely, for existing shareholders, implementing a covered call by selling the $5.00 strike for a 15-cent premium could yield a 7.52% total return if the stock is called away by the November 7th expiration. If the stock remains below the strike, a scenario with a 37% probability, the premium provides a 26.56% annualized return boost while retaining the underlying shares. Both strategies leverage the high implied volatility to generate income or define entry/exit points, but cap potential gains, underscoring the need for a clear fundamental thesis on the underlying stock.

Key Decisions for Investors

• Investors should recognize the significant premium in implied volatility (231-237%) over historical volatility (91%), which makes selling options premium a more statistically attractive strategy than buying it at current levels.
• For investors bullish on RXRX but seeking a lower entry point, selling the $4.50 cash-secured put offers a method to either acquire shares at an effective 6% discount or generate a 9.42% annualized return on the committed capital.
• Current shareholders with a neutral to moderately bullish outlook could consider the covered call at the $5.00 strike to generate a substantial annualized yield (26.56%), but must accept capping their upside and potentially selling their shares at $5.00.
• Before executing either strategy, it is critical to perform fundamental due diligence on Recursion Pharmaceuticals, as these options tactics are designed to express a pre-existing investment view, not to replace it.